Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient

Restricted access

The incidence of acute myeloid leukemia (AML) increases with age, with a median age at diagnosis of 67 years. Older patients have inferior responses to chemotherapy, including not only lower complete remission rates but also short disease-free survival in those who do achieve complete remission. For older patients with a high likelihood of response to chemotherapy, recent data support dose intensification and strong consideration of allogeneic hematopoietic stem cell transplantation. For those unlikely to benefit from chemotherapy because of disease- and/or patient-related factors, novel agents and approaches are being pursued. Agents currently available or under study include the nucleoside analogs clofarabine and sapacitabine, the demethylating agents decitabine and azacitidine, the immunomodulatory agent lenalidomide, and the farnesyl transferase inhibitor tipifarnib. These agents may be administered in the outpatient setting, thus AML in older patients is increasingly becoming an outpatient diagnosis. Additionally, novel agents may prolong survival without inducing complete remissions, and therefore the goals and end points of therapy are also shifting. AML in older patients is a very active current area of investigation.

Correspondence: Maria R. Baer, MD, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201. E-mail: mbaer@umm.edu
  • 1.

    AltekruseSFKosaryCLKrapchoM. SEER Cancer Statistics Review 1975–2007 National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2007/. Accessed January 18 2011.

    • Search Google Scholar
    • Export Citation
  • 2.

    AppelbaumFRGundackerHHeadDR. Age and acute myeloid leukemia. Blood2006;107:34813485.

  • 3.

    KantarjianHRavandiFO'BrienS. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood2010;116:44224429.

    • Search Google Scholar
    • Export Citation
  • 4.

    LeithCPKopeckyKJGodwinJ. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood1997;89:33233329.

    • Search Google Scholar
    • Export Citation
  • 5.

    WhitmanSPMaharryKRadmacherMD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood2010;116:36223626.

    • Search Google Scholar
    • Export Citation
  • 6.

    LöwenbergBOssenkoppeleGJvan PuttenW. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med2009;361:12351248.

    • Search Google Scholar
    • Export Citation
  • 7.

    PautasCMerabetFThomasX. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol2010;28:808814.

    • Search Google Scholar
    • Export Citation
  • 8.

    RossDDDoyleLAYangW. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol1995;50:16731683.

    • Search Google Scholar
    • Export Citation
  • 9.

    FaragSSMaharryKPerezW. Allogeneic hematopoietic stem cell transplantation (HCT) compared to chemotherapy only in acute myeloid leukemia (AML) patients 60 years and older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/Cancer and Leukemia Group B (CALGB) study [abstract]. Blood2009;114(Suppl):Abstract 657.

    • Search Google Scholar
    • Export Citation
  • 10.

    FaderlSGarcia-ManeroGEstrovZ. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol2010;28:27552760.

    • Search Google Scholar
    • Export Citation
  • 11.

    KantarjianHMErbaHPClaxtonD. Phase II study of clofarabine monotherapy in previously untreated older patients with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol2010;28:549555.

    • Search Google Scholar
    • Export Citation
  • 12.

    BurnettAKRussellNHKellJ. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol2010;28:23892395.

    • Search Google Scholar
    • Export Citation
  • 13.

    FaderlSVerstovsekSCortesJ. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood2006;108:4551.

    • Search Google Scholar
    • Export Citation
  • 14.

    FaderlSRavandiFHuangX. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood2008;112:16381645.

    • Search Google Scholar
    • Export Citation
  • 15.

    SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacytidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:38953903.

    • Search Google Scholar
    • Export Citation
  • 16.

    FenauxPMuftiGJHellstrom-LindbergE. Azacytidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol2010;28:562569.

    • Search Google Scholar
    • Export Citation
  • 17.

    LubbertMRuterBClausR. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [abstract]. Blood2007;110(Suppl):Abstract 300.

    • Search Google Scholar
    • Export Citation
  • 18.

    CashenAFSchillerGJO'DonnellMRDiPersioJF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol2010;28:556561.

    • Search Google Scholar
    • Export Citation
  • 19.

    BlumWGarzonRKlisovicRB. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A2010;107:74737478.

    • Search Google Scholar
    • Export Citation
  • 20.

    FehnigerTAUyGLTrinkausK. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood2011;117:18281833.

    • Search Google Scholar
    • Export Citation
  • 21.

    FehnigerTAByrdJCMarcucciG. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood2009;113:10021005.

    • Search Google Scholar
    • Export Citation
  • 22.

    LancetJEGojoIGotlibJ. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood2007;109:13871394.

    • Search Google Scholar
    • Export Citation
  • 23.

    RaponiMLancetJEFanH. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood2008;111:25892596.

    • Search Google Scholar
    • Export Citation
  • 24.

    HarousseauJLMartinelliGJedrzejczakWW. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood2009;114:11661173.

    • Search Google Scholar
    • Export Citation
  • 25.

    KarpJEFlattenKFeldmanEJ. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood2009;113:48414852.

    • Search Google Scholar
    • Export Citation
  • 26.

    KantarjianHGarcia-ManeroGO'BrienS. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol2010;28:285291.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 32 27 0
PDF Downloads 9 9 0
EPUB Downloads 0 0 0